210
Participants
Start Date
May 18, 2021
Primary Completion Date
February 1, 2026
Study Completion Date
March 31, 2026
Berubicin
Berubicin HCl is a novel synthetic anthracycline with a chemical structure similar to doxorubicin HCl, a cytotoxic anthracycline topoisomerase II inhibitor isolated from cultures of Streptomyces peucetius var. caesius.
Lomustine
"Lomustine is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as an alkylating agent."
University Hospital Zurich, Zurich
Roswell Park Cancer Center, Buffalo
Milton S. Hershey Medical Center, Hershey
Duke University School of Medicine, Durham
Piedmont Healthcare, Atlanta
Baptist MD Anderson Cancer Center, Jacksonville
Mayo Clinic Florida, Jacksonville
Baptist Miami, Miami
University of Kentucky, Lexington
Ohio State University, Columbus
University of Wisconsin Hospital and Clinics, Madison
Rush University Cancer Center, Chicago
University of Nebraska Medical Center, Omaha
Tulane Cancer Center Clinic, New Orleans
University of Arkansas, Little Rock
Baylor Research Institute, Dallas
University of Texas Health Science Center at Houston, Houston
Texas Oncology PA, Austin
HCA Healthcare Research Institute, Englewood
Huntsman Cancer Center, Salt Lake City
Southern California Permanente Medical Group, Los Angeles
Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica
University of Califonia San Diego Moores Cancer Center, San Diego
University of California Irvine, Orange
University of California San Francisco, San Francisco
Providence Health, Portland
Swedish Medical Center, Seattle
Mayo Clinic, Rochester
Tufts Medical Center, Boston
UMass (ACC) - Hollings Cancer Center (HCC), Worcester
Hackensack Meridian Health, Hackensack
Rutgers University, Piscataway
Atlantic Healthcare, Summit
Hopital Pierre Wertheimer, Lyon
Hopital de La Timone, Marseille
Institut de Recherche en Cancerologie de Montpellier, Montpellier
Hopital Pitie-Salpetriere, Paris
Institut de Cancerologie de l'Ouest, Saint-Herblain
nstitut Universitaire du Cancer de Toulouse-, Toulouse
Institut de Cancerologie Gustave-Roussy, Villejuif
Servizio Sanitario Regionale Emilia-Romagna - Azienda USL di Bologna - Ospedale Bellaria, Bologna
Istituto Clinico Humanitas, Milan
Hospital Universitari Germans Trias i Pujol, Badalona
Hospital Duran i Reynals, L'Hospitalet de Llobregat
Hospital Ramón y Cajal, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Regional Universitario de Malaga Carlos Haya, Málaga
Hospital Universitario Virgen Macarena, Seville
Lead Sponsor
Collaborators (1)
Worldwide Clinical Trials
OTHER
CNS Pharmaceuticals, Inc.
INDUSTRY